This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Miromatrix Medical Inc. (MIRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 10.81% and 9,200%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session.
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $66.28 in the latest trading session, marking a +1.33% move from the prior day.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $65.41, moving +1.93% from the previous trading session.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Exact Sciences (EXAS) Stock Moves -0.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $64.36, marking a -0.16% move from the previous day.
Exact Sciences (EXAS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $64.46, marking a +1.45% move from the previous day.
Exact Sciences (EXAS) Stock Moves -1.42%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $66.08 in the latest trading session, marking a -1.42% move from the prior day.
Exact Sciences (EXAS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $62.45, marking a +0.19% move from the previous day.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week
by Nalak Das
The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Earnings Season Could Be Great for Exact Sciences (EXAS)
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $65.52 in the latest trading session, marking a +0.17% move from the prior day.